Dimension Therapeutics, Inc. has received $-0.54 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $-0.6 while the top line estimate is $-0.48 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -20%.
Dimension Therapeutics, Inc. results fell short with a surprise EPS of -13.73% or $-0.07. The Actual EPS was $-0.58 compared to the Estimated EPS of $-0.51 during its most recent quarterly earnings.
In the last quarter, Dimension Therapeutics, Inc. reported Annual Earnings of $-0.58. Based on the filings, last years Annual Earnings was, $-4.41. In the last Quarter, DMTX reported a surprise Earnings per Share of -13.73% . The consensus estimate for current quarter is $-0.54 and for the current fiscal year, the estimate is $-2. For the Next fiscal year, the estimate is $-2.4 based on the consensus.
Dimension Therapeutics, Inc. (NASDAQ:DMTX) stock ended Tuesday session in the red zone in a volatile trading. The stock closed down 2.3 points or 54.12% at $1.95 with 1,674,276 shares getting traded. Post opening the session at $2.75, the shares hit an intraday low of $1.9 and an intraday high of $2.81 and the price was in this range throughout the day. The company has a market cap of $49 million and the number of outstanding shares has been calculated to be 25,043,506 shares. The 52-week high of Dimension Therapeutics, Inc. (NASDAQ:DMTX) is $10.47 and the 52-week low is $1.9.
Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The companys pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts.